Full Press Release Details
Creative Medical Technology Holdings
Files Patent on Anti-aging Technology Using AmnioStem Stem Cells
Creative Medical Technology Holdings announced today filing
of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversing
Previous studies by the Company have demonstrated that AmnioStemTM
cells secrete factors that are capable of rejuvenating aged cells. By encapsulating the cells outside of the body, so that the
cells are in contact with the patient's circulation, the cells are permitted to secrete factors that may reduce aging, without
having to inject the cells in the patient.
The concept of using cells that are growing outside of the body
as a means of modifying physiological activities has previously been performed and appears feasible. Specifically, similar approaches
to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure. A clinical
trial demonstrated feasibility of using cell culture of hepatocytes to act as a "liver assist device". These devices
are currently in Phase 3 of clinical trials1,2.
The filed patent describes a similar approach to those used
in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStemTM
amniotic fluid derived stem cells.
"Previous studies from Stanford University3
and Harvard University4 have shown
that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice
induce an anti-aging/rejuvenating effects on organs/tissues of aged mice. Through this patent, we are aiming to recapitulate this
effect, in an ethical and technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief Scientific Officer.
"What is stunning about the AmnioStemTM stem cell, which was licensed by the Company from the University of California
San Diego, is that it possesses many regenerative features but is collected from non-controversial sources."
The AmnioStemTM stem cell is derived from amniotic
fluid during the process of amniocentesis. Amniotic fluid is typically considered medical waste. Scientists at University of California
San Diego have developed means of extracting and growing stem cells from the amniotic fluid. These stem cells have been published
to be capable of treating animal models of numerous diseases including stroke5,
heart attack6, liver failure7,
colitis8, diabetes9,
emphysema10, and kidney injury11.
An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making
them "universal donor" stem cells.
"The concept of using young blood to stimulate regeneration
in aged individuals is attracting much attention in the area of regenerative medicine. I am enthusiastic about the approach being
developed by Creative Medical Technology Holdings, which overcomes some of the important roadblocks that prevent implementation
of this novel and promising approach." Said Amit Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and coinventor
"At Creative Medical Technology Holdings we are committed
to advancing regenerative medicine to various areas of human suffering. In contrast to other conditions, aging will occur in everyone."
Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "While the field of anti-aging medicine
is filled with various false hopes and hype, we are attempting to address this problem cautiously and methodologically through
testing our technology for safety and efficacy."
"Our goal is to continue to internally develop and patent
technology in the regenerative medicine space and to broaden our patent portfolio for future commercialization by the company and/or
with other life science companies with complementary technology.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
Timothy Warbington Chief Executive Officer 480-789-9939